Entering text into the input field will update the search result below

FDA defers action on Novartis/BeiGene's tislelizumab for esophagus cancer citing inspection woes

Jul. 14, 2022 6:44 AM ETBeiGene, Ltd. (BGNE) Stock, NVS StockBy: Ravikash Bakolia, SA News Editor

Esophageal cancer, illustration

Dr_Microbe

  • The U.S. Food and Drug Administration (FDA) deferred action on approving BeiGene (NASDAQ:BGNE) and Novartis' (NYSE:NVS) tislelizumab for esophageal cancer as the agency was unable to carry out required inspections in China due to COVID-19 related travel restrictions.
  • BeiGene's

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
NVS
--
BGNE
--